About iSTAR Medical
iSTAR Medical SA, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally.
iSTAR Medical has exclusive rights to the STAR® material from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. According to Market Scope, the fast-growing MIGS market is expected to reach $1.1bn worldwide by 2023.
iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.